OR1L6

Across TCGA pan-cancer cohorts, OR1L6 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated OR1L6 data layer compared with 7 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher OR1L6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OR1L6 expression acts as an unfavorable survival marker.

SARC, STAD, and PRAD are the cancer types where OR1L6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	OS	Median	All	0.178	0.745	.008	6	view →
STAD	DFS	Median	II,III,IV	0.089	0.615	<.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

OR1L6–SARC (OS)

Open the SARC breakdown →